Weight Loss and CLOCK 3111T/C Polymorphism
Launched by HACETTEPE UNIVERSITY · Feb 20, 2023
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a specific gene variant called CLOCK 3111T/C and how it may relate to weight, eating habits, sleep patterns, and health in people who are overweight or obese. The researchers want to find out if people with this gene variant have different eating habits, sleep schedules, or responses to weight loss diets compared to those with normal body weight. To do this, they will gather information through questionnaires, measure participants' body size and weight, and analyze blood samples to look for the gene variant and certain hormones related to metabolism.
To join the study, participants need to be between 20 and 50 years old. Those who are overweight should have a body mass index (BMI) between 25 and 40, while individuals with normal weight should have a BMI between 18.5 and 24.9. The trial is currently recruiting participants, and those who qualify will follow a weight loss diet for three months while providing information about their eating and activity levels. This study could help us understand how genetics may influence weight loss and overall health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Be in the 20-50 age range
- • BMI in the range of 25-40 kg/m2 for the study group
- • BMI of 18.5-24.9 kg/m2 for the control group
- Exclusion Criteria:
- • Those with type 1 diabetes
- • Those with Type 2 diabetes who take insulin therapy or use oral diabetes medication
- • Those who use drugs for weight loss
- • Those with unstable cardiovascular disease
- • Those with kidney or liver failure
- • Presence of diagnosed malabsorption (celiac disease, Crohn's, ulcerative colitis)
- • Those who have undergone bariatric surgery
- • Those who are pregnant or breastfeeding
- • Menopausal women
- • Those who use corticosteroids
- • Those with severe endocrine disorders (hypothyroidism, hyperthyroidism, hypopituitarism)
- • Those with psychiatric or neurological disease
- • Weight change of \>5% in the last 6 months
- • Those with malignant tumors
- • Those with eating disorders
- • Shift workers
- • Relatives
- • People from different ethnic backgrounds
About Hacettepe University
Hacettepe University is a leading research institution in Turkey, renowned for its commitment to advancing medical science and healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, the university supports a wide range of clinical trials aimed at improving patient outcomes and developing new therapeutic approaches. Hacettepe University is dedicated to maintaining the highest ethical standards and regulatory compliance in its research endeavors, fostering an environment that promotes scientific excellence and contributes to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, , Turkey
Patients applied
Trial Officials
Hanife Seda Oğuz Baykal, Dr
Study Chair
Hacettepe University
Erdem Karabulut, Prof
Study Chair
Hacettepe University
Neslişah Rakıcıoğlu, Prof
Study Director
Hacettepe University
Hande Gül Ulusoy Gezer, MSc
Principal Investigator
Hacettepe University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials